Cargando…

Flow rate variance of a fully implantable pump for the delivery of intravenous treprostinil in pulmonary arterial hypertension

Implantable infusion pumps might improve the convenience and safety of intravenous treprostinil for pulmonary arterial hypertension. The LENUS Pro® pump (approved in Europe) has a fixed flow rate. Based on 126 pumps and 2853 refills, we retrospectively analyzed the actual flow rate from 09/2010 to 0...

Descripción completa

Detalles Bibliográficos
Autores principales:	Richter, Manuel J., Harutyunova, Satenik, Bollmann, Tom, Classen, Simon, Fuge, Jan, Gall, Henning, Gerhardt, Felix, Ghofrani, Hossein A., Gunkel, Hartmut, Grünig, Ekkehard, Halank, Michael, Heine, Alexander, Klose, Hans, Lange, Tobias J., Neurohr, Claus, Nickolaus, Kai, Opitz, Christian F., Rosenkranz, Stephan, Seyfarth, Hans-Jürgen, Tello, Khodr, Ewert, Ralf, Olsson, Karen M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074510/ https://www.ncbi.nlm.nih.gov/pubmed/32206306 http://dx.doi.org/10.1177/2045894020910136

Ejemplares similares

Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension
por: Eichstaedt, Christina A., et al.
Publicado: (2022)

Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Harzheim, Dominik, et al.
Publicado: (2013)

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
por: Marra, Alberto M., et al.
Publicado: (2018)

Impact of SARS-CoV-2 pandemic on pulmonary hypertension out-patient clinics in Germany: a multi-centre study
por: Yogeswaran, Athiththan, et al.
Publicado: (2020)

Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial
por: Ehlken, Nicola, et al.
Publicado: (2016)

Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study
por: Konstantinides, Stavros V., et al.
Publicado: (2016)

Is iron deficiency caused by BMPR2 mutations or dysfunction in pulmonary arterial hypertension patients?
por: Theobald, Vivienne, et al.
Publicado: (2023)

EIF2AK4 mutation as “second hit” in hereditary pulmonary arterial hypertension
por: Eichstaedt, Christina A., et al.
Publicado: (2016)

Myeloproliferative Diseases as Possible Risk Factor for Development of Chronic Thromboembolic Pulmonary Hypertension—A Genetic Study
por: Eichstaedt, Christina A., et al.
Publicado: (2020)

Intravenous treprostinil via an implantable pump in pediatric pulmonary arterial hypertension
por: Desole, Susanna, et al.
Publicado: (2018)

Practical management of riociguat in patients with pulmonary arterial hypertension
por: Halank, Michael, et al.
Publicado: (2019)

Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centres
por: Wissmüller, Max, et al.
Publicado: (2022)

Exercise Training Improves Exercise Capacity and Quality of Life in Patients with Inoperable or Residual Chronic Thromboembolic Pulmonary Hypertension
por: Nagel, Christian, et al.
Publicado: (2012)

Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study( )
por: Valerio, Luca, et al.
Publicado: (2022)

Mutually reinforcing effects of genetic variants and interferon-β 1a therapy for pulmonary arterial hypertension development in multiple sclerosis patients
por: Lerche, Marianne, et al.
Publicado: (2019)

Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry
por: Hoeper, Marius M., et al.
Publicado: (2022)

COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension
por: Hoeper, Marius M., et al.
Publicado: (2022)

Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri(®)): a prospective, 6-months, open label, observational, non-interventional study
por: Degering, Julia, et al.
Publicado: (2023)

Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up
por: Xanthouli, Panagiota, et al.
Publicado: (2020)

Monotherapy in patients with pulmonary arterial hypertension at four German PH centres
por: Stubbe, Beate, et al.
Publicado: (2021)

Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil
por: Chapman, Richard W., et al.
Publicado: (2021)

Thin Air Resulting in High Pressure: Mountain Sickness and Hypoxia-Induced Pulmonary Hypertension
por: Grimminger, Jan, et al.
Publicado: (2017)

Validity of echocardiographic tricuspid regurgitation gradient to screen for new definition of pulmonary hypertension
por: Gall, Henning, et al.
Publicado: (2021)

Prognostic meaning of right ventricular function and output reserve in patients with systemic sclerosis
por: Xanthouli, Panagiota, et al.
Publicado: (2022)

Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis
por: Schmidt, Kai-Helge, et al.
Publicado: (2023)

Prognostic Relevance of Cardiopulmonary Exercise Testing for Patients with Chronic Thromboembolic Pulmonary Hypertension
por: Ewert, Ralf, et al.
Publicado: (2022)

Right heart size and function significantly correlate in patients with pulmonary arterial hypertension – a cross-sectional study
por: Fischer, Lukas, et al.
Publicado: (2018)

Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy
por: Knudsen, Lars, et al.
Publicado: (2011)

Treprostinil for pulmonary hypertension
por: Skoro-Sajer, Nika, et al.
Publicado: (2008)

Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2013)

Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis
por: Hoeper, Marius M, et al.
Publicado: (2022)

Advanced risk stratification of intermediate risk group in pulmonary arterial hypertension
por: Yogeswaran, Athiththan, et al.
Publicado: (2020)

Acute response to rapid iloprost inhalation using the Breelib™ nebulizer in pulmonary arterial hypertension: the Breelib™ acute study
por: Richter, Manuel J., et al.
Publicado: (2019)

Oxygenated hemoglobin as prognostic marker among patients with systemic sclerosis screened for pulmonary hypertension
por: Xanthouli, Panagiota, et al.
Publicado: (2023)

Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial
por: White, R. James, et al.
Publicado: (2020)

The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinil
por: Jansa, Pavel, et al.
Publicado: (2023)

Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH
por: Gall, Henning, et al.
Publicado: (2018)

Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity?
por: Theobald, Vivienne, et al.
Publicado: (2022)

Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil
por: Kingrey, John F., et al.
Publicado: (2023)

Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension
por: Kamp, Jan C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0s3c09230mugr1jf0cvo4mab9g